Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Vyepti (eptinezumab-jjmr) is indicated for the preventive treatment of migraine in adults.
• This summary is based on the review of 15 systematic review(s)/meta-analysis(es). ^[1-15]
• Reduction in Monthly Migraine Days (MMDs): Eptinezumab demonstrated a significant reduction in monthly migraine days compared to placebo, with a mean difference (MD) ranging from -1.43 to -1.56 days across various studies. The 300 mg dose was particularly effective, achieving a reduction of -2.46 days in a network meta-analysis.
• Responder Rates: Eptinezumab increased the ≥75% responder rate (RR = 1.80) and the ≥50% responder rate (RR = 1.46) compared to placebo. These effects were consistent across both episodic and chronic migraine populations.
• Comparative Effectiveness: Among anti-CGRP monoclonal antibodies, eptinezumab 300 mg showed the highest efficacy in reducing monthly headache days, outperforming other similar medications like erenumab, fremanezumab, and galcanezumab in specific analyses.
• Population Consistency: The effectiveness of eptinezumab was consistent across different populations, including both episodic and chronic migraine patients, with no significant differences observed based on demographic factors such as age, gender, body mass index, or migraine duration.
• Eptinezumab showed no significant increase in treatment-related adverse events (RR = 1.01, 95% CI 0.94, 1.10) or serious adverse events (RR = 0.93, 95% CI 0.46, 1.90) compared to placebo, with most adverse events being mild or moderate.
• Common adverse events included nasopharyngitis, which was mostly unrelated to the study drug, and hypersensitivity reactions observed in 1.1% of patients, which were generally non-serious and resolved with standard treatment.
• No significant differences in the incidences of treatment-emergent adverse events or serious adverse events were noted among different anti-CGRP monoclonal antibodies, and infusion-site adverse events were rare, leading to infusion interruption in a small percentage of patients.